NCT01976507View on ClinicalTrials.gov

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

PHASE4CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Atrial FibrillationAtrial Flutter
Interventions
DRUG

dabigatran etexilate mesylate

Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Vanderbilt University Medical Center

OTHER

NCT01976507 - Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism | Biotech Hunter | Biotech Hunter